You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020126012
Dec 202025012
Jan 202166010
Feb 20211403
Mar 20214209
Apr 20212806
May 202131017
Jun 2021007
Jul 2021009
Aug 2021003
Sep 2021004
Oct 202114024
Nov 202126014
Dec 20213205
Jan 20222100
Feb 20222405
Mar 20223205
Apr 202213604
May 20223400
Jun 20223804
Jul 20222401
Aug 20222804
Sep 20224007
Oct 20222001
Nov 20221403
Dec 20223001
Jan 20232000
Feb 20232803
Mar 20232203
Apr 2023803
May 20232201
Jun 2023600
Jul 20231001
Aug 20231602
Sep 2023801
Oct 20231803
Nov 20232602
Dec 20232801
Jan 20242400
Feb 20247201
Mar 20241000
Apr 20241201
May 20243001
Jun 20245502
Jul 20243400
Aug 20242003
Total13140198